Amgen’s Q1 Overshadowed By Tax Dispute That May Cost $7.1bn To Resolve
IRS Identifies $5.1bn Shortfall, Proposes $2bn Penalty
Executive Summary
First quarter revenue of $6.2bn and product sales of $5.7bn were up 6% and 2%, respectively, year over year. However, a looming – and potentially growing – tax liability is a multibillion-dollar overhang.
You may also be interested in...
Amgen/Takeda ASCO Data Could Help Guide Vectibix Use In mCRC
The PARADIGM study took place in Japan, but it was described as the first to prospectively evaluate treatment of wild-type RAS mCRC and left-sided primary tumors.
Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars
Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.
Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars
Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.